

Seagen Secure Updates

Recently, Seagen Secure (now part of Pfizer Patient Assistance Program) implemented changes to the Patient Assistance Program (PAP).* The program changes will be implemented January 1, 2025, and are as follows:

2025 PAP Changes


Effective January 1, 2025, the new PAP program requirements for Medicare Part D patients who are requesting assistance with a Pfizer product covered under their plan are:

- 1. Patients must enroll in the Medicare Prescription Payment Plan prior to requesting assistance.
- 2. Patients must attest to the following on their enrollment form:
 - a. Enrollment in the Medicare Prescription Payment Plan.
 - b. Awareness of their monthly copayment and annual out-of-pocket maximum for covered medicines, which will be \$2,000 for most Medicare Part D patients.
 - c. Inability to afford their co-payment.
 - d. Have not met their annual out-of-pocket maximum (after which they would have a \$0 co-payment for covered medicines).
- 3. Additionally, to be eligible for the PAP in 2025, Medicare Part D patients must also:
 - Meet the annual pre-tax household income eligibility requirement of at or below 300% of the Federal Poverty Level (FPL). For more information on the Federal Poverty Level guidelines visit: https://aspe.hhs.gov/topics/poverty-economic-mobility/povertyquidelines.
 - Have a valid prescription for a Pfizer medicine available in the PAP.
 - c. Have a valid prescription for an FDA-approved indication for the requested medicine.
 - d. Be uninsured or publicly insured via government-provided insurance and unable to afford their copayment. Public insurance includes, but is not limited to, Medicare, Medicaid, Champus/TRICARE, and VA. Commercially insured patients are not eligible.
 - e. Reside in the U.S. or a U.S. covered territory (U.S. covered territories include U.S. Virgin Islands, Guam, and Puerto Rico)
 - Be treated by a healthcare provider licensed in the U.S. or a covered U.S. territory (U.S. covered territories include U.S. Virgin Islands, Guam, and Puerto Rico

*For applicable programs/products: The grace period for patients currently enrolled with an annual pre-tax household income between 301%-500% of the FPL ends on December 31, 2025.

In addition to the PAP, Pfizer will continue to provide other assistance programs that offer patients information regarding if/how their insurance may cover their

The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™.







prescriptions, copay support, and information about independent third-party assistance options via Seagen Secure and other patient support programs.

We encourage patients to consult with their healthcare provider and/or insurance provider to explore the options that best address their healthcare and financial needs.

2025 PAP Changes

Recently, Pfizer implemented changes to the Seagen Secure Patient Assistance Program (PAP):

The program changes will be implemented January 1, 2025, and are as follows:

- 1. The income eligibility requirement for all products within the PAP will be 300% of the FPL, adjusted for household size (HH).
- All new patients applying to the PAP for 2025 enrollment must meet the new income eligibility requirement of at or below 300% of the FPL, adjusted for HH size.
- 3. Patients who are **currently enrolled** in the PAP with income at or above 300% up to 500% of the FPL, adjusted for HH size, may apply for re-enrollment and be eligible to continue receiving their medicine in 2025 if they meet all other eligibility requirements listed below.

Other eligibility criteria that have not changed for the PAP in 2025 are as follows:

- 1. A valid prescription for a Pfizer medicine available in the PAP is required.
- 2. This prescription must be for an FDA-approved indication for the requested medicine(s).
- 3. Patients must be uninsured or publicly insured via government-provided insurance and unable to afford their copayment. Public insurance includes Medicare, Medicaid, Champus/TRICARE, and VA. Commercially insured patients are not eligible.
- 4. Reside in the U.S. or a U.S. covered territory (U.S. covered territories include U.S. Virgin Islands, Guam, and Puerto Rico)
- 5. Treatment must be provided by a healthcare provider licensed in the U.S. or a covered U.S. territory (U.S. covered territories include U.S. Virgin Islands, Guam, and Puerto Rico)

We recognize that these program changes may be significant for certain patients. In addition to the PAP, Seagen Secure will continue to provide other assistance with information regarding how patients' insurance may cover their prescriptions, copay support, and other patient support programs. Eligibility services may vary based on specific medicines and conditions.

We encourage patients to consult with their healthcare provider and/or insurance provider to explore the options that best address their healthcare and financial needs. There are other resources that may be able to help, depending on the medicine, such as NeedyMeds, RxOutreach (among others), commercial copay cards (restrictions apply), and local pharmacy savings programs.

The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation™ is a separate legal entity from Pfizer Inc., with distinct legal restrictions.

